Adrenocortical carcinoma radiation therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RT}} {{MAD}} | {{CMG}}; {{AE}} {{RT}} {{MAD}} | ||
==Overview== | ==Overview== | ||
[[Radiation therapy]]and [[radiofrequency ablation]] may be used for [[palliative care|palliation]] in patients who are not surgical candidates. Recurrence is lower in | [[Radiation therapy]]and [[radiofrequency ablation]] may be used for [[palliative care|palliation]] in patients who are not surgical candidates. Recurrence is lower in patients with [[Radiotherapy|adjuvant radiotherapy]] than in patients without [[Radiation therapy|radiotherapy]]. ACC with metastasis to bone experienced adequate pain relief after [[radiotherapy]]. | ||
==Radiation Therapy== | ==Radiation Therapy== | ||
[[Radiotherapy]] has shown improvement in both the [[Adjuvant treatment|adjuvant]] and [[Palliative care|palliative]] ACCs. | [[Radiotherapy]] has shown improvement in both the [[Adjuvant treatment|adjuvant]] and [[Palliative care|palliative]] ACCs. | ||
Revision as of 15:01, 26 September 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma radiation therapy On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma radiation therapy |
|
Risk calculators and risk factors for Adrenocortical carcinoma radiation therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Mohammed Abdelwahed M.D[3]
Overview
Radiation therapyand radiofrequency ablation may be used for palliation in patients who are not surgical candidates. Recurrence is lower in patients with adjuvant radiotherapy than in patients without radiotherapy. ACC with metastasis to bone experienced adequate pain relief after radiotherapy.
Radiation Therapy
Radiotherapy has shown improvement in both the adjuvant and palliative ACCs.
Radiation therapy in non-metastatic ACC
- According to the National Cancer Data Base and The Surveillance, Epidemiology, and End Results program, there is an evidence that radiotherapy might be effective.[1]
- Local recurrence-free survival was 86% in the group that received radiation compared with11%in those that did not.[2]
- Radiotherapy also can be used for treating unresectable masses.[3]
Radiation therapy for palliation
- Seventy-seven percent of patients with metastatic ACCs to bone experienced adequate palliation of pain after radiotherapy with dosages totaling 10 to 60 Gyger.[4]
- Radiofrequency ablation (RFA) and transarterial chemoembolization are an alternative to surgery when surgery is not desired or contraindicated.
- High local tumor regression can be achieved can be achieved with minimal systemic side effects.[5]
- Bleeding is one of the complications as adrenal tumors have a tendency to undergo hemorrhage.[6]
References
- ↑ Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H; et al. (2006). "Outcomes of adrenal cortical carcinoma in the United States". Surgery. 140 (6): 914–20, discussion 919-20. doi:10.1016/j.surg.2006.07.035. PMID 17188138.
- ↑ Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M; et al. (2006). "Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma". J Clin Endocrinol Metab. 91 (11): 4501–4. doi:10.1210/jc.2006-1007. PMID 16895957.
- ↑ Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E (2011). "Adjuvant and definitive radiotherapy for adrenocortical carcinoma". Int J Radiat Oncol Biol Phys. 80 (5): 1477–84. doi:10.1016/j.ijrobp.2010.04.030. PMID 20675074.
- ↑ Markoe AM, Serber W, Micaily B, Brady LW (1991). "Radiation therapy for adjunctive treatment of adrenal cortical carcinoma". Am J Clin Oncol. 14 (2): 170–4. PMID 1709336.
- ↑ Thacker PG, Friese JL, Loe M, Biegler P, Larson M, Andrews J (2009). "Embolization of nonliver visceral tumors". Semin Intervent Radiol. 26 (3): 262–9. doi:10.1055/s-0029-1225667. PMC 3036499. PMID 21326571.
- ↑ de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A; et al. (2010). "Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization". Ann Surg Oncol. 17 (8): 2081–9. doi:10.1245/s10434-010-0979-2. PMID 20237856.